The Bronchopulmonary Dysplasia Drug Market is attracting pharmaceutical and biotechnology investment as companies explore new approaches for neonatal respiratory disease. The market is projected to expand from USD 2.1 billion in 2025 to USD 3.5 billion by 2035, with research partnerships playing an important role in strengthening the therapeutic pipeline.

The report identifies collaborations involving major pharmaceutical companies as notable developments. Novartis announced a partnership in March 2025 focused on expanding its neonatal respiratory portfolio, while Pfizer reported a June 2025 collaboration to advance an inhaled therapy for BPD. Roche also entered a strategic collaboration in May 2024 involving research into neonatal lung diseases, including BPD.

The development landscape spans antioxidants, anti-inflammatory drugs, bronchodilators, and surfactants. Surfactants remain a significant category, while continued research into therapies addressing inflammation and oxidative stress could diversify available treatment approaches. The report also points to combination therapies integrating corticosteroids with novel biologics as an area of opportunity.

Research institutions and pharmaceutical companies have opportunities to use AI and machine learning to analyze patient data and support more personalized neonatal treatment strategies. Collaboration with academic institutions may also accelerate discovery by combining specialized research expertise with commercial drug-development capabilities.

As awareness of the long-term impact of BPD increases, market participants are likely to focus on early diagnosis, innovative therapies, clinical research, and improved delivery systems. Continued partnerships could help expand the development pipeline and encourage new approaches to addressing the needs of premature infants and other vulnerable patient groups.